AML

Update from AML human trial in MiamiMay 4, 2022

Who is entitled to enroll in the trial:
AML /Hi-Risk MDS patients with:

8 weeks of life expectancy.
clinically deteriorating.
have no more available treatments.

In cohort 1 (dose=6mg/m^2) three patients were enrolled.

The first patient was alive with this dose for 5 months.
The second patient was alive with this dose for 1.5 months.
The third

04 May|

PHASE 1B/2A Clinical trial startedApril 13, 2021

The Nerofe Phase 1B/2A trial with high risk MDS and AML patients is taking place at the University of Miami Sylvester Comprehensive Cancer Center.

13 Apr|